1/9/2009 | SS | Market Commentary: Analyst sees Elan, Pfizer combo unlikely; DOJ studies Centennial buyout; Crucell moves on deal talk
|
10/23/2006 | BT | Crucell looking for larger share of the $10 billion vaccine market
|
10/9/2006 | BT | Market Commentary: New River rises 61.5%, Shire up 16% on ADHD drug nod; Coley eyed; NeoPharm higher by 20%
|
9/26/2006 | BT | Crucell and National Institutes of Health start Ebola vaccine trial
|
9/26/2006 | BT | WHO grants prequalification to Crucell's Quinvaxem vaccine
|
9/14/2006 | BT | Crucell, Novartis to evaluate antibodies using STAR technology
|
9/8/2006 | BT | Crucell says Berna Biotech delisted, last trading day Sept. 15
|
9/7/2006 | BT | Crucell signs European STAR licensing agreement
|
8/29/2006 | BT | Crucell revenues up for six-month period, R&D spending increases
|
8/17/2006 | BT | Crucell, DSM Biologics agreement gives MorphoSys access to PER.C6 for its antibody program
|
7/18/2006 | BT | Crucell suspends Aerugen development after failure in phase 3 study
|
7/10/2006 | BT | Invitrogen is first licensing partner for Crucell, DSM Biologics PER.C6 vendor network
|
6/28/2006 | BT | DSM, Crucell appoint Medarex VP as CEO of its newly formed PER.C6 R&D center
|
6/20/2006 | BT | Crucell licenses PER.C6 to Immuno-Biological Laboratories
|
6/13/2006 | BT | Crucell plans to double sales of vaccines within three years, Quinvaxem a major driver of growth
|
5/31/2006 | BT | Crucell to begin human clinical trial with avian influenza vaccine
|
5/31/2006 | BT | Market Commentary: Gentium gains on PIPE; Cubist holders await convertible smoke to clear; Crucell up; Durect higher
|
5/23/2006 | BT | Crucell focused on integration in 2006 following acquisition of Berna
|
5/22/2006 | BT | Crucell, BIOA&D form agreement to develop ceNOS technology
|
5/16/2006 | BT | Crucell agreement gives Upstate use of PER.C6 cell line
|
5/9/2006 | BT | Crucell ends PER.C6 patent infringement case as Cevec agrees not to misuse cell bank
|
4/27/2006 | BT | Crucell to expand focus in growing vaccine market
|
4/12/2006 | BT | Crucell files to cancel minority shares in Berna Biotech
|
4/6/2006 | BT | Millennium, Crucell sign agreement for production of monoclonal antibodies
|
4/5/2006 | BT | Crucell to divest Graub, the veterinary business of Berna Biotech
|
3/27/2006 | BT | Crucell gets Korean approval for pediatric vaccine drug Quinvaxem
|
3/27/2006 | BT | Dynavax to buy Rhein Biotech from Crucell for $12 million
|
3/14/2006 | BT | Crucell, DSM Biologics announce PER.C6 licensing agreement with UCB
|
3/9/2006 | BT | Crucell, DSM Biologics announce PER.C6 licensing agreement with UMN Pharma
|
2/22/2006 | BT | Crucell completes acquisition of Berna Biotech with 97% of shares tendered
|
1/23/2006 | BT | Crucell's offer for Berna Biotech shares receives 73.9% acceptance
|
1/18/2006 | BT | Ark Therapeutics extends PER.C6 licensing deal with Crucell
|
1/10/2006 | BT | Novartis says it's not interested in acquiring Berna while Crucell's bid to buy the vaccines maker progresses
|
1/5/2006 | BT | Crucell licenses STAR technology to XOMA
|
12/22/2005 | BT | Crucell signs three PER.C6 cell line deals
|
12/21/2005 | BT | Crucell signs PER.C6 licenses with ZyStor Therapeutics, Ferring Pharmaceuticals
|
12/20/2005 | BT | Crucell, DSM to expand PER.C6 licensing business
|
12/19/2005 | BT | Crucell signs antibody license with Genzyme
|
12/16/2005 | BT | Crucell to begin phase 1 trial of West Nile Virus vaccine
|
12/8/2005 | BT | Crucell licenses PER.C6 cell line for an infectious disease to Vakzine Projekt Management
|
12/1/2005 | BT | Crucell makes an all-share offer to acquire vaccines-maker Berna Biotech in deal valued at CHF591 million
|
11/23/2005 | BT | Crucell in licensing agreement with Tibotec for PER.C6 cell line
|
11/2/2005 | BT | Crucell teams with ACE Biosciences to develop antibodies to treat hospital-acquired infections
|
10/19/2005 | BT | Crucell, DSM Biologics license cell line to IQ for anthrax antibodies
|
10/13/2005 | BT | Crucell receives underperform rating from Jefferies
|
7/21/2005 | BT | Acambis, Crucell poised to strengthen, Merrill vaccine biodefense report says
|
5/10/2005 | PP | Crucell arranges private placement of stock
|